Posted by Michael Wonder on 03 Aug 2016
Nivolumab in advanced lung cancer: evidence for significant additional benefits
1 August 2016 - Advantages in overall survival and side effects.
Nivolumab has been approved since April 2016 for the treatment of adults with locally advanced or metastatic non-squamous non-small-cell lung cancer who have already received chemotherapy. In an early benefit assessment, the IQWiG has investigated whether nivolumab offers advantages over the appropriate comparator therapy in these patients.
There is an indication of a significant additional benefit of nivolumab versus docetaxel. For patients for whom the use of docetaxel or similar drugs is not possible, an additional clinical benefit over the appropriate comparator therapy (best supportive care) has not been shown.
